Skip to main content

Zegfrovy

Pronunciation: zeg-FROH-vee
Generic name: sunvozertinib
Dosage form: oral tablets (150 mg, 200 mg)

Medically reviewed by Carmen Pope, BPharm. Last updated on Jul 9, 2025.

What is Zegfrovy?

Zegfrovy is used to treat non-small cell lung cancer (NSCLC) that is locally advanced or has metastasized and with an abnormal epidermal growth factor receptor (EGFR) gene, in adults whose disease has worsened while on or after chemotherapy that contains platinum. It is an oral tablet taken 1 time a day.

Zegfrovy is a targeted drug that works by blocking EGFR, a protein that promotes cancer growth. It specifically targets EGFR exon 20 insertion mutations found in some lung cancers. In laboratory clinical trials, it effectively stopped cancer cell growth and shrank tumors in animal models with these specific mutations. Zegfrovy belongs to the drug class called kinase inhibitors.

Zegfrovy (sunvozertinib) gained FDA approval on July 2, 2025. There is no generic.

FDA approvals and uses

Zegfrovy is used to treat adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy.

Your healthcare provider will perform a test to make sure that Zegfrovy is right for you.

It is not known if Zegfrovy is safe and effective in children.

Side effects

The most common side effects of Zegfrovy include:

The most common severe abnormal laboratory test results with Zegfrovy include:

Zegfrovy may affect fertility in females and males, which may affect your ability to have a child. Talk to your healthcare provider if this is a concern for you.

Serious side effects and warnings

Zegfrovy may cause the following serious side effects:

These are not all of the possible side effects of Zegfrovy. Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.

Before taking

Before taking Zegfrovy, tell your healthcare provider about all of your medical conditions, including if you:

Pregnancy

Zegfrovy can harm your unborn baby. Females who are able to become pregnant:

Talk to your healthcare provider about birth control methods that might be right for you during this time. Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with Zegfrovy.

Males who have female partners who can become pregnant:

Breastfeeding

It is not known if Zegfrovy passes into your breast milk. Do not breastfeed during treatment with Zegfrovy and for 2 weeks after your last dose of Zegfrovy. Talk to your healthcare provider about the best way to feed your baby during treatment with this medicine.

How should I take Zegfrovy?

Take Zegfrovy exactly as your healthcare provider tells you. Do not change your dose or stop taking this medicine unless your healthcare provider tells you to.

Dosing information

Dose of Zegfrovy for NSCLC in Adults

What happens if I miss a dose?

If you miss a dose of Zegfrovy, take it as soon as you remember within 12 hours. If it has been more than 12 hours, skip the missed dose and take your next dose at your regularly scheduled time.

If you vomit after taking a dose of Zegfrovy, do not take an extra dose. Take your next dose at your regularly scheduled time.

What other drugs will affect this medicine?

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Zegfrovy may affect the way other medicines work and other medicines may affect how Zegfrovy works. Especially tell your healthcare provider if you take:

This is not a complete list of interactions. You can use the Drugs.com Drug Interaction Checker to check your other medications against Zegfrovy for interactions.

Does Zegfrovy interact with my other drugs?

Enter medications to view a detailed interaction report using our Drug Interaction Checker.

Storage

Store Zegfrovy at room temperature between 68°F to 77°F (20°C to 25°C).

Keep out of the reach of children.

Ingredients

Active ingredient: sunvozertinib

Pronunciation: zeg-FROH-vee
Generic name: sunvozertinib
Dosage form: oral tablets (150 mg, 200 mg)

Company

Pronunciation: zeg-FROH-vee
Generic name: sunvozertinib
Dosage form: oral tablets (150 mg, 200 mg)

More about Zegfrovy (sunvozertinib)

Related treatment guides

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.